Publications by authors named "W Thomas London"
Purpose: Novel therapies targeting specific genomic alterations are a promising treatment approach for relapsed/refractory cancer. Patients with specific alterations may be more likely to respond. Trial designs should maximize opportunities for such patients to enroll on these trials.
View Article and Find Full Text PDFPurpose: The fragility index (FI) is an adjunctive metric to facilitate the interpretation of p-values in clinical trials. The FI has not been studied in phase 3 trials in pediatric oncology.
Methods: PubMed was used to identify phase 3 pediatric oncology trials published between 1980 and 2020.
Article Synopsis
- Tumor invasion of the spinal canal occurs in about 15% of newly diagnosed neuroblastoma patients, prompting a need for effective treatment strategies that optimize survival while minimizing long-term effects.
- A study of 92 intermediate-risk neuroblastoma patients with intraspinal tumors revealed that nearly half were symptomatic at diagnosis, but most of them experienced complete resolution of symptoms following treatment, regardless of the initial severity or duration of their deficits.
- The findings suggest that while prompt diagnosis and chemotherapy are crucial, surgical options like laminectomy may not significantly improve motor symptoms, indicating that surgery should be reserved for cases with rapid worsening neurologic conditions.
Article Synopsis
- The study analyzed trends in the diagnosis of venous thromboembolism (VTE) and arterial ischemic stroke (AIS) in pediatric patients during the COVID-19 pandemic, using data from the Pediatric Health Information Systems database from 2018 to 2021.
- The rate of VTE diagnoses increased by 28.6% during the pandemic years compared to previous years, while AIS rates remained stable; COVID-19 diagnosis was linked to a higher likelihood of VTE but not AIS.
- Utilization of pharmacological thromboprophylaxis doubled during the pandemic, especially among patients with COVID-19, indicating a significant response in treatment approaches despite the rising rates of VTE.